eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | intestinal disease |
| Symptom | C0024523|malabsorption |
| Sentences | 12 |
| PubMedID- 24555478 | Other exclusion criteria were history or clinical evidence of coronary and/or valvular heart disease, congestive heart failure, hyperlipidaemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, or chronic pancreatitis; history of malignant disease, alcohol or drug abuse, or liver or kidney failure; and any treatments interfering with glucose or vitamin d metabolism. |
| PubMedID- 23028545 | Other exclusion criteria were history or clinical evidence of coronary and valvular heart disease, congestive heart failure, hyperlipidemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure and treatments able to modify glucose metabolism. |
| PubMedID- 22399698 | Subjects were excluded if they had gastrointestinal diseases associated with bleeding or malabsorption, chronic pancreatitis, history of any malignant disease, history of drug abuse, positivity for antibodies to hepatitis c virus or hepatitis b surface antigen, and anemia, defined according to the world health organization criteria as a hemoglobin concentration <13 g/dl in men and <12 g/dl in women. |
| PubMedID- 21922352 | It may be the result of inadequate intake or malabsorption in children with gastrointestinal diseases including cystic fibrosis, α1-antitrypsin deficiency, and biliary atresia. |
| PubMedID- 21076576 | Subjects were excluded from the study if they had a history of cardiovascular disease including peripheral atherosclerosis, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, and treatments able to modify glucose metabolism, such as steroid. |
| PubMedID- 23200965 | Materials and methods: the present study retrospectively analyzed the determinants of urolithiasis in 51 patients with fat malabsorption due to different intestinal diseases. |
| PubMedID- 22545220 | The diagnostic criteria for nphpt were as follows: apart from normal serum calcium and high pth levels, serum 25ohd levels above 30 ng/ml, absence of bisphosphonates, thiazide diuretics, anticonvulsants or lithium use, glomerular filtration rate greater than 60 ml/min, using the formula modification of diet in renal disease (mdrd), and the absence of other metabolic bone diseases or gastrointestinal diseases associated with malabsorption or liver disease. |
| PubMedID- 21515837 | Other exclusion criteria were history or clinical evidence of coronary and valvular heart disease, congestive heart failure, hyperlipidemia, peripheral vascular disease, chronic gastrointestinal disease associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, and treatment to modify glucose metabolism. |
| PubMedID- 22011411 | Other exclusion criteria were history or clinical evidence of coronary and/or valvular heart disease, congestive heart failure, hyperlipidemia, hyperuricemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, or chronic pancreatitis; history of malignant disease, alcohol or drug abuse, or liver or kidney failure; and treatments able to modify glucose or ua metabolism. |
| PubMedID- 26243847 | Also, patients with gastrointestinal disease associated with malabsorption were excluded. |
| PubMedID- 21911775 | Other exclusion criteria were history or clinical evidence of coronary or valvular heart disease, congestive heart failure, hyperlipidemia, peripheral vascular disease, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, and treatments able to modify glucose metabolism. |
| PubMedID- 22164268 | Subjects, aged 23–70 years, were excluded if they had history of cardiovascular disease, including peripheral atherosclerosis, chronic gastrointestinal diseases associated with malabsorption, chronic pancreatitis, history of any malignant disease, history of alcohol or drug abuse, liver or kidney failure, or received treatments able to modify glucose metabolism including glucose-lowering, lipid-lowering and antihypertensive therapy. |
Page: 1